Although leuko-araiosis is a common finding on computed tomographic (CT) scans of the brain, its pathogenesis remains uncertain. To investigate the association between blood pressure (BP) disturbances and leuko-araiosis, we retrospectively reviewed CT scans and 24-hour ambulatory blood pressure monitorings of 79 elderly patients (57 women and 22 men; mean age: 83.3 ± 6.4 years). Of the 79 patients, 50 were demented (30 had Alzheimer’s disease and 18 vascular dementia) and 29 were not demented. The leuko-araiosis score (LA score) was determined by using Rezek’s scale. To evaluate short-term variation of BP, we determined (1) the variability of systolic and diastolic BPs (SBP, DBP; within-subject standard deviation of all readings over a 24-hour period), (2) the coefficient of variability (variability of BP/mean BP) and (3) the maximal variation of BP (difference between the maximum and minimum 24-hour BPs). Higher LA scores were associated with higher SBPs in 24-hour, diurnal and nocturnal periods, higher maximal variation of SBP, greater variability of SBP during 24-hour, diurnal and nocturnal periods and greater coefficient of variability of SBP during sleep. Our study suggests that elevations and short-term variations of SBP may contribute to the pathogenesis of white matter lesions in elderly persons.

Keywords:
White matter lesions, Blood pressure variability, Hypertension, Ambulatory blood pressure monitoring
1.
Hachinski VC, Potter P, Merskey H: Leuko-araiosis. Arch Neurol 1987;44:21–23.
2.
Erkinjuntti T: Differential diagnosis between Alzheimer’s disease and vascular dementia: Evaluation of common clinical methods. Acta Neurol Scand 1987;76:433–442.
3.
Inzitari D, Diaz F, Fox A, Hachinski VC, Steingart A, Lau C, Donald A, Wade J, Mulic H, Merskey H: Vascular risk factors and leuko-araiosis. Arch Neurol 1987;44:42–47.
4.
Aharon-Peretz J, Cummings JL, Hill MA: Vascular dementia and dementia of Alzheimer type. Cognition, ventricular size, and leuko-araiosis. Arch Neurol 1988;45:719–721.
5.
Rezek DL, Morris JC, Fulling KH, Gado MH: Periventricular white matter lucencies in senile dementia of the Alzheimer type and in normal aging. Neurology 1987;37:1365–1368.
6.
Fein G, Van Dyke C, Davenport L, Turetsky B, Brant-Zawadzki M, Zatz L, Dillon W, Valk P: Preservation of normal cognitive functioning in elderly subjects with extensive white matter lesions of long duration. Arch Gen Psychiatry 1990;47:220–223.
7.
Kobari M, Meyer JS, Ichijo M: Leukoaraiosis, cerebral atrophy, and perfusion in normal aging. Arch Neurol 1990;47:161–165.
8.
Longstreth WT Jr, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, Enright PL, O’Leary D, Fried L: Clinical correlates of white matter findings on cranial magnetic imaging of 3,301 elderly people. The cardiovascular health study. Stroke 1996;27:1274–1282.
9.
Van Swieten JC, Geyskes GG, Derix MM, Peeck BM, Ramos LM, van Latum JC, van Gijn J: Hypertension in the elderly is associated with white matter lesions and cognitive decline. Ann Neurol 1991;30:825–830.
10.
Van Swieten JC, Kappelle LJ, Algra A, van Latum JC, Koudstaal PJ, van Gijn J: Hypodensity of the cerebral white matter in patients with transient ischemic attack or minor stroke: Influence on the rate of subsequent stroke. Dutch TIA Trial Study Group. Ann Neurol 1992;32:177–183.
11.
Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson L-A, Nilsson L, Persson G, Odén A, Svanborg A: 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141–1145.
12.
Liao D, Cooper L, Cai J, Toole JF, Bryan N, Hutchinson RG, Tyroler HA: Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study. Stroke 1996;27:2262–2270.
13.
Hénon H, Godefroy O, Lucas C, Pruvo JP, Leys D: Risk factors and leukoaraiosis in stroke patients. Acta Neurol Scand 1996;94:137–144.
14.
Brayne C, Gill C, Huppert FA, Barkley C, Gehlhaar E, Girling DM, O’Connor DW, Paykel ES: Vascular risks and incident dementia: Results from a cohort study of the very old. Dement Geriatr Cogn Disord 1998;9:175–180.
15.
Diaz JF, Merskey H, Hachinski VC, Lee DH, Boniferro M, Wong CJ, Mirsen TR, Fox H: Improved recognition of the relationship between leukoaraiosis and cognitive impairment in Alzheimer’s disease. Arch Neurol 1991;48:1022–1025.
16.
Erkinjuntti T, Sulkava R, Palo J, Ketonen L: White matter low attenuation on CT in Alzheimer’s disease. Arch Gerontol Geriatr 1989;8:95–104.
17.
Leys D, Pruvo JP, Parent M, Vermersch P, Soetaert G, Steinling M, Delacourte A, Defossez A, Rapoport A, Clarisse J, Petit H: Could Wallerian degeneration contribute ‘to leuko-araiosis’ in subjects free of any vascular disorder? J Neurol Neurosurg Psychiatry 1991;54:46–50.
18.
Pasquier F, Leys D: Why are stroke patients prone to develop dementia? J Neurol 1997;244:135–142.
19.
Tatemichi TK, Desmond DW, Mayeux R, Paik M, Stern Y, Sano M, Remien RH, Williams JB, Mohr JP, Hauser WA: Dementia after stroke: Baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology 1992;42:1185–1193.
20.
DeCarli C, Murphy DGM, Tranh M, Grady CL, Haxby JV, Gillette JA, Salerno JA, Gonzales-Aviles A, Horwiz B, Rapoport SI, Schapiro MB: The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology 1995;45:2077–2084.
21.
Matsubayashi K, Okumiya K, Wada T, Osaki Y, Fujisawa M, Doi Y, Ozawa T: Postural dysregulation in systolic blood pressure is associated with worsened scoring on neurobehavioral function tests and leukoaraiosis in the older elderly living in the community. Stroke 1997;28:2169–2173.
22.
Lopez OL, Becker JT, Jungreis CA, Rezek D, Estol C, Boller F, DeKosky ST: Computed tomography- but not magnetic resonance imaging-identified periventricular white matter lesions predict symptomatic cerebrovascular disease in probable Alzheimer’s disease. Arch Neurol 1995;52:659–664.
23.
Brun A, Englund E: A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study. Ann Neurol 1986;19:253–262.
24.
Janota I, Mirsen TR, Hachinski VC, Lee D, Merskey H: Neuropathological correlates of leukoaraiosis. Arch Neurol 1989;46:1124–1128.
25.
Pantoni L, Garcia JH: Pathogenesis of leukoaraiosis. A review. Stroke 1997;28:652–659.
26.
Skoog I: A review on blood pressure and ischaemic white matter lesions. Dement Geriatr Cogn Disord 1998;9:13–19.
27.
Matsushita K, Kuriyama Y, Nagatsuka K, Nakamura M, Sawada T, Omae T: Periventricular white matter lucency and cerebral blood flow autoregulation in hypertensive patients. Hypertension 1994;23:565–568.
28.
Bakker SLM, de Leeuw FE, de Groot JC, Hofman A, Koudstaal PJ, Breteler MMB: Cerebral vasomotor reactivity and cerebral white matter lesions in the elderly. Neurology 1999;52:578–583.
29.
Goldstein IB, Bartzokis G, Hence DB, Shapiro D: Relationship between blood pressure and subcortical lesions in healthy elderly people. Stroke 1998;29:765–772.
30.
Tohgi H, Chiba K, Kimura M: Twenty-four-hour variation of blood pressure in vascular dementia of the Binswanger type. Stroke 1991;22:603–608.
31.
Shimada K, Kawamoto A, Matsubayashi K, Nishinaga M, Kimura S, Ozawa T: Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens 1992;10:875–878.
32.
Sander D, Winbeck K, Klingelhöfer J, Conrad B: Extent of cerebral white matter lesions is related to changes of circadian blood pressure rhythmicity. Arch Neurol 2000;57:1302–1307.
33.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services. Task Force on Alzheimer’s disease. Neurology 1984;34:939–944.
34.
Roman GC, Tatemichi TK, Erkinjuntti T, et al: Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250–260.
35.
O’Brien E, Mee F, Atkins N, O’Malley K: Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society protocol. J Hypertens 1991;9:573–574.
36.
Scheltens P, Erkinjuntti T, Leys D, Wahlund L-O, Inzitari D, del Ser T, Pasquier F, Barkhof F, Mäntyla R, Bowler J, Wallin A, Ghika J, Fazekas F, Pantoni L: White matter changes on CT and MRI: An overview of visual rating scales. Eur Neurol 1998;39:80–89.
37.
Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K: Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996;27:130–135.
38.
Mc Quinn BA, O’Leary DH: White matter lucencies on computed tomography, subacute arteriosclerotic encephalopathy (Binswanger’s disease), and blood pressure. Stroke 1987;18:900–905.
39.
Raiha I, Tarvonen S, Kurki T, Rajala T, Sourander L: Relationship between vascular factors and white matter low attenuation of the brain. Acta Neurol Scand 1993;87:286–289.
40.
Kohara K, Jiang Y, Igase M, Takata Y, Fukuoka T, Okura T, Kitami Y, Hiwada K: Postprandial hypotension is associated with asymptomatic cerebrovascular damage in essential hypertensive patients. Hypertension 1999;33:565–568.
41.
Meredith PA, Perloff D, Mancia G, Pickering T: Blood pressure variability and its implications for antihypertensive therapy. Blood Press 1995;4:5–11.
42.
Shimada K, Kawamoto A, Matsubayashi K, Ozawa T: Silent cerebrovascular disease in the elderly. Correlation with ambulatory pressure. Hypertension 1990;16:692–699.
43.
Lip GYH, Gibbs CR, Beevers G: Ambulatory blood pressure monitoring and stroke. More questions than answers. Stroke 1998;29:1495–1497.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.